Fuzuloparib vs. Apatinib for Advanced Ovarian Cancer PFS
Okay, here’s a breakdown of the key data from the provided text, focusing on the study and its findings:
Key Findings:
* Combination Therapy Not Beneficial: The study found that adding the antiangiogenic agent apatinib to the PARP inhibitor fuzuloparib did not improve progression-free survival (PFS) in patients with BRCA-mutated or homologous recombination deficiency-positive (HRD) ovarian cancer. This is the primary takeaway.
Study Details (FZOCUS-1):
* Name: FZOCUS-1
* Design: Multicenter, 2-stage, randomized study.
* Participants:
* Age 18-75
* Newly diagnosed ovarian,fallopian tube,or primary peritoneal cancer
* Stage III or IV disease
* Underwent surgery (primary debulking or neoadjuvant therapy with interval debulking)
* Received 6-9 cycles of platinum-based chemotherapy with a complete or partial response
* Good performance status (ECOG 0 or 1)
* Adequate organ function
* Treatment Arms (Randomization 2:2:1):
- Fuzuloparib (100mg twice daily) + Apatinib (375mg daily)
- Fuzuloparib (150mg twice daily)
- Placebo
* Timing of Treatment: Started within 12 weeks of completing platinum-based chemotherapy.
* Primary Endpoint: Progression-Free Survival (PFS) – assessed by blinded independant central review.
* Secondary Endpoints: Investigator-assessed PFS,Overall Survival.
Fuzuloparib Background:
* Approved in China (December 2020): For platinum-sensitive recurrent ovarian cancer,fallopian tube cancer,or primary peritoneal cancer with a BRCA mutation,after second-line or later chemotherapy.
* Later Approved in China: For frontline maintenance treatment of advanced ovarian cancer (based on interim data from FZOCUS-1).
In essence, the study investigated whether combining two drugs would be more effective than fuzuloparib alone, but the results showed no benefit from the combination in the specific patient population studied.